These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22696594)

  • 1. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.
    Coulouarn C; Cavard C; Rubbia-Brandt L; Audebourg A; Dumont F; Jacques S; Just PA; Clément B; Gilgenkrantz H; Perret C; Terris B
    Carcinogenesis; 2012 Sep; 33(9):1791-6. PubMed ID: 22696594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
    Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX
    Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
    Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
    Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
    Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
    J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
    Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
    Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiregional analysis of combined hepatocellular-cholangiocarcinoma reveals histologic diversity and molecular clonality.
    Na HY; Kim JH; Kim H; Cho JY; Han HS; Jang ES; Kim JW; Jeong SH; Heo J; Kim JW; Kim JW; Ahn S
    Histopathology; 2024 Jan; 84(2):402-408. PubMed ID: 37903726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma.
    Groeschl RT; Turaga KK; Gamblin TC
    J Surg Oncol; 2013 May; 107(6):608-12. PubMed ID: 23386397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma.
    Tang W; Guo Q; Qu X; Inagaki Y; Seyama Y; Midorikawa Y; Gai R; Kokudo N; Sugawara Y; Nakata M; Makuuchi M
    Oncol Rep; 2007 Apr; 17(4):737-41. PubMed ID: 17342308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells.
    Yang W; Yan HX; Chen L; Liu Q; He YQ; Yu LX; Zhang SH; Huang DD; Tang L; Kong XN; Chen C; Liu SQ; Wu MC; Wang HY
    Cancer Res; 2008 Jun; 68(11):4287-95. PubMed ID: 18519688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.
    Garancini M; Goffredo P; Pagni F; Romano F; Roman S; Sosa JA; Giardini V
    Liver Transpl; 2014 Aug; 20(8):952-9. PubMed ID: 24777610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases.
    Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M
    Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma.
    Dahmani R; Just PA; Perret C
    Clin Res Hepatol Gastroenterol; 2011 Nov; 35(11):709-13. PubMed ID: 21778132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
    Heringlake S; Hofdmann M; Fiebeler A; Manns MP; Schmiegel W; Tannapfel A
    J Hepatol; 2010 Feb; 52(2):220-7. PubMed ID: 20036025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
    Tischoff I; Tannapfel A
    Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma.
    Koh KC; Lee H; Choi MS; Lee JH; Paik SW; Yoo BC; Rhee JC; Cho JW; Park CK; Kim HJ
    Am J Surg; 2005 Jan; 189(1):120-5. PubMed ID: 15701504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.
    Li R; Yang D; Tang CL; Cai P; Ma KS; Ding SY; Zhang XH; Guo DY; Yan XC
    BMC Cancer; 2016 Feb; 16():158. PubMed ID: 26917546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/β-catenin signaling.
    Liu Y; Zhou R; Yuan X; Han N; Zhou S; Xu H; Guo M; Yu S; Zhang C; Yin T; Wu K
    Oncotarget; 2015 Apr; 6(11):8621-34. PubMed ID: 25940701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spalt-like transcription factor 4 immunopositivity is associated with epithelial cell adhesion molecule expression in combined hepatocellular carcinoma and cholangiocarcinoma.
    Tanaka Y; Aishima S; Kohashi K; Okumura Y; Wang H; Hida T; Kotoh K; Shirabe K; Maehara Y; Takayanagi R; Oda Y
    Histopathology; 2016 Apr; 68(5):693-701. PubMed ID: 26267070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.